Wanbury successfully completes USFDA inspection at its API facility in Patalganga Plant

01 Oct 2016

Wanbury has successfully completed US Food and Drug Administration (USFDA) inspection a at its API facility in Patalganga Plant, Maharashtra. The audit was carried out for a period of 4 days from September 26 to September 29, 2016 and concluded successfully. This is the second plant to be approved by USFDA this year, as earlier Tanuku Plant got approval two months ago in July 2016.

Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation. The company’s major thrust area lies in Active Pharmaceutical Ingredient (API) sale in over 70 countries and Pan-India Formulation presence.


Related Wanbury Ltd. Links:

Wanbury Share Price

33.10 0.00 (0.00%) Sep 22, 18:03
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 512.45
Dr. Reddys Lab 5203.45
Lupin 1029.65
Piramal Enterprises 1258.40
Cadila Healthcare 389.25
View more..
Sensex vs Wanbury
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback